

Programme & speakers

Day 1 - Tuesday 27th June 2017

08.45 Registration & welcome coffee

09.15 - 09.30 Welcome Address

09.30 - 11.00 Keynote Session I: ADCs, Empowering Cancer Therapy

Chairperson: **Nicolas Joubert, Université de Tours**



Antibody-Drug Conjugates for Cancer: Current Progress and Future Prospects.

Ravi Chari, Ph.D. - Vice President, Chemistry & Biochemistry, Distinguished Research fellow - **Immunogen**



Advancement in Antibody Drug Conjugates: A Step Closer to Magic Bullets in War against Cancer

- Advancement in ADCs unleashing a strong clinical pipeline of very promising anticancer drugs
- Five Rights of ADCs, meeting the challenges of off-target toxicities
- Translational approaches to ADC development

Rakesh Dixit, Ph.D., DABT - Vice President R & D, Global Head, Biologics Safety Assessment - **MedImmune Inc.**

11.00 - 11.30 Coffee Break and Poster Session - Partnering (B2B meetings)

11.30 - 12.15 Session II - part 1: Discovery of Novel ADCs Targets and Formats

Chairperson: **Maxime Lampilas, Sanofi**



Anthracycline-based ADCs :


Anthracycline-based antibody drug conjugates with potent immune-stimulatory functions

Roger Beerli, Ph.D. - Chief Scientific Officer - **NBE Therapeutics**



Sponsored presentation

Tissue Screen : the tissue based approach to target relevant protein

Renaud Burrer - R&D Manager - 

12.15 - 13.30 Lunch and Poster Session - Partnering (B2B meetings)

13.30 - 15.00 Session II - part 2: Discovery of Novel ADCs Targets and Formats



An auristatin-based anti-HER3 ADC enhances the efficacy of radiation therapy in pancreatic cancer

Thierry Chardès, Pharm. D., Ph.D. - CNRS Research Director - **Research Institute of Cancerology in Montpellier - LabEx MabImprove**



Small is Beautiful - Humabody® Drug Conjugates, HDCs a Real Alternative to ADCs

Thomas Sandal - Vice President R&D - **Crescendo Biologics**



The two faces of interleukin-2; engineering towards applications in oncology and autoimmune diseases
Ekkehard Moessner, Ph.D. - Head of Protein Engineering - **Roche Innovation Center, Large Molecules Research**

15.00 - 15.30 Coffee Break and Poster Session - Partnering (B2B meetings)

15.30 - 18.30 Pitch Session - New ADC Formats: Diagnostic and Immunomonitoring

Chairpersons: **Andreas Pahl, Heidelberg Pharma** - **Saïd El Alaoui, Covalab**

Pitch # 1 :

Gokhan YAHIOGLU - Antikor Biopharma

Not too big - Not too small : Fragment Drug Conjugates (FDCs) as alternatives to ADCs for solid tumors

Pitch # 2 :

Mathieu CINIER - Affilogic

Nanofitins as a versatile platform for cancer imaging and drug conjugates

Pitch # 3 :

Bruno TILLIER - Synthelis

Cell-free expression as an innovative tool for antigen production

Pitch # 4 :

Jonathan SJÖGREN - Genovis

The novel site specific ADC technology GlyCLICK preserves immunoreactivity and allows quantitative conjugation of functional groups to antibody Fc-glycans

Pitch # 5 :

David BONNAFOUS - McSAF

New linker technologies of ADC & bioconjugates developments

Pitch # 6 :

Jean VIALLET - Inovotion

INOVOTION Tests for drug discovery: Early identification of low value ADC

Pitch # 7 :

Thibault JONCKHEERE - ImmunXperts

Early Immunogenicity and Immunotoxicity Assessment and Risk Management for ADCs

Pitch # 8 :

Oreda BOUSSADIA - Epivax

The ISPRI Toolkit Rapidly Screens ADC Candidates for Immunogenic Potential Driven by T cell Epitope Content and Foreignness

Pitch # 9 :

Serge DESMOULINS - Agilent

Drug-to-antibody ratio determination for ADCs in serum enabled by a sample preparation platform that automates affinity purification and deglycosylation

Pitch # 10 :

Lisa RECNİK - ICRM-IBMM

Development of an Antibody Radiolabeled Drug Conjugate (ARDC) using 195mPt-Carboplatin for Theranostic Approach in Ovarian Cancer

Pitch # 11 :

Jean-Marc JOUMIER - EasyChelators

C-functionalized Cyclam derivatives as bifunctional chelating agent (BCA) analogues of TETA, TE2A and CB-TE2A

18.30 End of Day 1

20.00 Gala Dinner

Day 2 - Wednesday 28th June 2017

08.15 Registration & welcome coffee

08.30 - 10.30 Session III - Accelerate the Development of the Next-Generation ADCs

Chairperson: **Alain Beck, Centre d'Immunologie Pierre Fabre**



CovIsoLink™: New bacterial transglutaminase Q-tag substrate for the development of site specific Antibody Drug Conjugates

Saïd El Alaoui, Ph.D. - Chief Executive Officer - **Covalab**



Enzymatic site specific conjugation using transglutaminase to obtain homogeneous ADC

François Romagné, Ph.D. - Scientific Director - **MI-mAbs**



Amanitin-based Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer Therapy

Andreas Pahl, Prof. Dr. - Chief Scientific Officer - **Heidelberg Pharma**



Development of new cryptophycins as promising tubulin binder payloads for ADCs

Marie-Priscille Brun, Ph.D. - Immunoconjugate Leader / Chemical biology group - **Sanofi**

10.30 - 11.00 Coffee Break and Poster Session - Partnering (B2B meetings)

11.00 - 12.30 Session IV - Challenges in ADC developability, scale-up and manufacturing

Chairperson: **François Romagné, MI-mAbs**



Keynote presentation

Insights of multilevel state-of-the art analytical methods for ADCs structural assessment

Alain Beck, PhD - Senior Director, Analytical Chemistry, New Biological Entities - **Centre d'Immunologie Pierre Fabre** - Associate Editor of **mAbs journal**



Sponsored presentation

ADC Easy Access : From the Lab to the Clinic

Régis Lelou - Senior Bioengineer - R&D Chemicals



Sponsored presentation

Integrated services for immuno-conjugate development and production:

Symbiotic combination of R&D expertise and industrial leadership for successful development of mAbs

Eric Devic, Ph. D. - Founder-President and COO - **GTP Technology**



Novasep's integrated solutions for ADC

François D'Hooge, Ph.D. - Head of Bioconjugation Unit - **Novasep**



Need for speed - how to accelerate the development of an ADC

Klaus Kaiser - Head of Downstream - **Bayer**

12.30 - 14.00 Lunch and Poster Session - Partnering (B2B meetings)

14.00 - 16.00 Session V - Moving ADCs Forward Into the Clinic: Safety and Efficacy

Chairperson: **François Lefoulon, Servier**



Update on PBDs

Philip Howard, Ph.D. - CSO, Senior Fellow - **Spirogen**



Mechanisms of resistance to ADCs

Charles Dumontet, Prof. Ph.D - Senior Physician in Hematology - **Hospices civils de Lyon**



Clinical pharmacology of ADCs

Gilles Paintaud, PU-PH - Head of CNRS UMR 7292 - **University of Tours** - **LabEx MabImprove**





ADC Safety & Toxicity: Technology Choices and Importance of Process Development to Control Safety related CQAs
Olivier Marcq, Ph.D. - Group leader Development and Manufacturing - **Agensys**

16.00 - 17.00 Outsourcing roundtable: mAbs and ADCs outsourcing, opportunities and challenges - Partnering (B2B meetings)

Chairperson: **Florence Lhospice**, Innate Pharma

Arnaud Martin, Director CMO Business - **Sanofi**

Régis Lelou, Senior Bioengineer - R&D Chemicals - **Lonza**

Christophe Aussourd, Planning and Supply Director - **Servier**

17.00 - 17.30 Closing Remarks, Announcement of the AIS2018

17.30 End of Symposium